zilebesiran (ALN-AGT) News

12 »

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Zilebesiran as Add-on Treatment to RAAS Inhibitors for Patients with Hypertension: Data from the KARDIA-2 and KARDIA-3 Phase 2 Trials (Focussed Oral Room 12) - Apr 13, 2026 - Abstract #ERA2026ERA_1073;

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Enrollment change, Trial initiation date, Adverse events:  ZENITH: Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (clinicaltrials.gov) -  Mar 31, 2026
P3, N=11000, Recruiting,  Sponsor: Alnylam Pharmaceuticals
N=3962 --> 11000

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
New P3 trial, Adverse events:  ZENITH: Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (clinicaltrials.gov) -  Mar 29, 2026
P3, N=3962, Recruiting,  Sponsor: Alnylam Pharmaceuticals

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Review, Journal: Zilebesiran: an RNA interference agent-its need and potential to transform hypertension treatment. (Pubmed Central) - Mar 1, 2026
Zilebesiran may redefine therapy in hypertension management through twice-yearly dosing that enhances adherence, ensures sustained BP control, and may reduce cardiovascular risk. Ongoing Phase III trials (ZENITH and KARDIA-3) will clarify its long-term efficacy, safety, and applicability across diverse populations, potentially establishing RNAi therapeutics as a new frontier in chronic hypertension treatment.

|||||||||| lorundrostat (MT-4129) / Mineralys Therap, zilebesiran (ALN-AGT) / Alnylam, Roche, baxdrostat (CIN-107) / AstraZeneca
Journal: New pharmacological therapies for hypertension. (Pubmed Central) - Jan 28, 2026
ASI therapies lorundrostat and baxdrostat are close to being licensed for HTN. Once commercially available and recommended in treatment guidelines, the next big challenge will be reimbursement and implementation model in different healthcare systems.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
POOLED SAFETY ANALYSIS OF ZILEBESIRAN, AN INVESTIGATIONAL LONG-ACTING RNA INTERFERENCE THERAPEUTIC, FROM PHASE 2 STUDIES IN PATIENTS WITH HYPERTENSION (Highlighted Original Research Stage, Posters, Hall E) - Jan 10, 2026 - Abstract #ACC2026ACC_8910;
Once commercially available and recommended in treatment guidelines, the next big challenge will be reimbursement and implementation model in different healthcare systems. Abstract is embargoed at this time.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Review, Journal: A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA. (Pubmed Central) - Dec 27, 2025
In the last fifty years different therapeutic strategies, including angiotensin converting enzyme inhibitors (ACEi), type 1 angiotensin II receptor blockers (ARBs) and angiotensin receptor neprilysin inhibitors (ARNi), have been developed to counteract this neurohormonal dysregulation. However, all these therapeutic strategies have a relatively short-term action and they need to be administered orally once or more times every day to achieve the therapeutic purposes with a risk of poor therapeutic adherence.More recently, the search for a new effective strategy to provide a long-term control of hypertension was recently boosted by the availability of novel technologies, such as the angiotensinogen suppression in the liver realized through the silencing of RNA with zilebesiran, a small interfering RNA (siRNA) agent.The purpose of this article is to review the available data on Zilebesiran and to discuss in detail potential advantages in the clinical use as well as the still unresolved potential risks.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Retrospective data, Review, Journal: Efficacy and Safety of Zilebesiran for the Management of Hypertension: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials. (Pubmed Central) - Oct 20, 2025
However, all these therapeutic strategies have a relatively short-term action and they need to be administered orally once or more times every day to achieve the therapeutic purposes with a risk of poor therapeutic adherence.More recently, the search for a new effective strategy to provide a long-term control of hypertension was recently boosted by the availability of novel technologies, such as the angiotensinogen suppression in the liver realized through the silencing of RNA with zilebesiran, a small interfering RNA (siRNA) agent.The purpose of this article is to review the available data on Zilebesiran and to discuss in detail potential advantages in the clinical use as well as the still unresolved potential risks. This meta-analysis confirms that Zilebesiran is consistently associated with significant reductions in both ambulatory and office blood pressure over 12 to 24 weeks, with an acceptable safety

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Efficacy of Zilebesiran in Hypertension: A Meta-analysis with Dose-Response and Angiotensinogen Correlation from KARDIA Trials (Population Science Zone' Moderated Digital Poster 11) - Oct 6, 2025 - Abstract #AHA2025AHA_7285;
However, no clear dose-response relationship or direct link between AGT suppression and SBP reduction was observed. These findings highlight the need for further trials with harmonized dosing and biomarker reporting to clarify predictors of response.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
KARDIA-3: A randomized trial of zilebesiran versus placebo on top of standard care for patients with hypertension and established cardiovascular disease or high cardiovascular risk with or without chronic kidney disease (Clinical Science Zone 1' Moderated Digital Poster 5) - Oct 6, 2025 - Abstract #AHA2025AHA_6719;
P2
These findings highlight the need for further trials with harmonized dosing and biomarker reporting to clarify predictors of response. Results of the KARDIA-3 trial, including patients with CKD, will characterize the efficacy and safety profile of zilebesiran in patients with uncontrolled hypertension despite standard care who are at high CV risk and will inform the design of a planned CVOT.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Journal: Zilebesiran Add-On Treatment for Inadequately Controlled Hypertension-Reply. (Pubmed Central) - Sep 24, 2025
Results of the KARDIA-3 trial, including patients with CKD, will characterize the efficacy and safety profile of zilebesiran in patients with uncontrolled hypertension despite standard care who are at high CV risk and will inform the design of a planned CVOT. No abstract available

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Journal: Zilebesiran Add-On Treatment for Inadequately Controlled Hypertension. (Pubmed Central) - Sep 24, 2025
No abstract available No abstract available

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
New P3 trial, Adverse events:  ZENITH: Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (clinicaltrials.gov) -  Sep 18, 2025
P3, N=11000, Recruiting,  Sponsor: Alnylam Pharmaceuticals

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Trial completion:  ALN-AGT01-006: A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension (clinicaltrials.gov) -  Aug 29, 2025
P1/2, N=36, Completed,  Sponsor: Alnylam Pharmaceuticals
No abstract available Active, not recruiting --> Completed

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Enrollment closed, Enrollment change:  A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers (clinicaltrials.gov) -  Aug 26, 2025
P1, N=42, Active, not recruiting,  Sponsor: Alnylam Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=78 --> 42

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk (Madrid(Main Auditorium); Online) - Jul 10, 2025 - Abstract #ESCWCC2025ESC_WCC_8670;

|||||||||| indapamide / Generic mfg., zilebesiran (ALN-AGT) / Alnylam, Roche
Clinical, Journal: Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial. (Pubmed Central) - Jul 1, 2025
P2
In patients with uncontrolled hypertension despite treatment with indapamide, amlodipine, or olmesartan, the addition of single-dose zilebesiran resulted in significant SBP reductions compared with placebo at 3 months, with low rates of serious adverse events. ClinicalTrials.gov Identifier: NCT05103332.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT (Zagreb(Hall 10)) - Jun 19, 2025 - Abstract #ESCWCC2025ESC_WCC_8572;
ClinicalTrials.gov Identifier: NCT05103332. Joint session with JAMA and JAMA Cardiology

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Review, Journal: Advancing antihypertensive drug development. (Pubmed Central) - Jun 3, 2025
RNA-based therapies, like zilebesiran, provide a novel approach to suppress angiotensinogen, offering durable antihypertensive effects with less frequent dosing...These emerging therapies not only aim to lower blood pressure but also address underlying pathophysiological mechanisms, offering a precision-focussed approach to treatment. By critically analysing these developments, this review provides insights into how novel strategies can overcome existing challenges in hypertension management, reduce the global disease burden and improve patient outcomes.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Journal: Zilebesiran: A Novel RNA Interference Therapeutic for Hypertension. (Pubmed Central) - Jun 2, 2025
Therapeutic applications under investigation include use as monotherapy in patients with essential hypertension and as an adjunct for patients with resistant hypertension or high cardiovascular risk. This manuscript provides a comprehensive overview of zilebesiran's mechanism of action, pharmacokinetics/pharmacodynamics, clinical trial evidence, potential role in hypertension management and related conditions, as well as its safety and tolerability profile, based on current peer-reviewed data.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Impact of zilebesiran, an investigational RNA interference therapeutic targeting hepatic angiotensinogen, on renin-angiotensin system biomarkers in patients with mild-to-moderate hypertension (Station 4(Research Gateway)) - May 15, 2025 - Abstract #ESCWCC2025ESC_WCC_4250;
AGT reductions with biannual and quarterly doses of zilebesiran were observed to Month 6 and were accompanied by decreases in serum angiotensin I and II concentrations and subsequent increases in plasma renin concentration, consistent with disruption of negative angiotensin II feedback on renin secretion with angiotensinogen inhibition. Pharmacodynamic effects were sustained for 6 months, without evidence of angiotensin escape, which together with previously reported long-lasting blood pressure-lowering effects, support a biannual dosing regimen for zilebesiran.

|||||||||| Review, Journal: Novel Antihypertensive Medications to Target the Renin-Angiotensin System: Mechanisms and Research. (Pubmed Central) - May 12, 2025
The current overview presents the latest research findings on the mechanisms through which novel anti-hypertensive medications target the RAS. These include zilebesiran (targeting angiotensinogen), PRO20 (targeting the renin/(pro)renin/PRR axis), sacubitril/valsartan (targeting the renin/ACE/Ang II/AT1R axis), GSK2586881, Ang (1-7) and AVE0991 (targeting the renin/ACE2/Ang (1-7)/MasR axis), alamandine (targeting the alamandine/MrgD receptor axis), C21 and ?-Pro7-Ang III (targeting the renin/ACE/Ang II/AT2R axis), EC33, and firibastat and NI956 (targeting brain Ang III).

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Review, Journal: Advancing hypertension management: the role of zilebesiran as an siRNA therapeutic agent. (Pubmed Central) - Mar 20, 2025
Its emergence highlights the ongoing evolution of cardiovascular pharmacology and underscores the importance of innovative approaches to address the global burden of hypertension. Moving forward, concerted efforts in research and clinical practice are necessary to realize the benefits of zilebesiran into hypertension management protocols, ultimately advancing cardiovascular health worldwide.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Retrospective data, Review, Journal: Safety and Efficacy of Novel RNA Interference Therapeutic Agent Zilebesiran in People With Hypertension: A Systematic Review and Meta-Analysis. (Pubmed Central) - Feb 18, 2025
This limits the generalizability of the results and highlights the need for further trials with a larger and more diverse study population. Further long-term investigations are also needed to establish the drug's impact on

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Enrollment closed:  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (clinicaltrials.gov) -  Jan 23, 2025
P2, N=375, Active, not recruiting,  Sponsor: Alnylam Pharmaceuticals
Further long-term investigations are also needed to establish the drug's impact on Recruiting --> Active, not recruiting

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Retrospective data, Review, Journal: Zilebesiran and Hypertension: A Systematic Review and Meta-analysis. (Pubmed Central) - Jan 12, 2025
Optimal dosing appears between 250 and 500 mg. Further research should explore patient-specific responses to enhance therapeutic efficacy and minimize side effects.

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Trial completion:  KARDIA-1: A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (clinicaltrials.gov) -  Dec 27, 2024
P2, N=394, Completed,  Sponsor: Alnylam Pharmaceuticals
Further research should explore patient-specific responses to enhance therapeutic efficacy and minimize side effects. Active, not recruiting --> Completed

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Enrollment open:  A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers (clinicaltrials.gov) -  Dec 16, 2024
P1, N=78, Recruiting,  Sponsor: Alnylam Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche, Tryvio (aprocitentan) / J&J, baxdrostat (CIN-107) / AstraZeneca
Review, Journal: Novel pharmacologic approaches in resistant hypertension. (Pubmed Central) - Dec 11, 2024
Recently, valsartan/sacubitrol and flozins have been increasingly used in resistant hypertension, which have been introduced for the treatment of diseases other than hypertension but can be a supplement to previously used drugs in resistant hypertension...The results to date allow for the consideration of aprocitentan (a drug that inhibits endothelin receptors) or baxdrostat or another new aldosterone synthesis inhibitor in the treatment of resistant hypertension that does not respond to 4 drugs, including spironolactone. Further studies are needed to confirm the efficacy and safety of these new drugs in the treatment of resistant hypertension.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Review, Journal: Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension? (Pubmed Central) - Dec 4, 2024
It was also difficult to reliably interpret the results of KARDIA-1 as blood pressure went up significantly in the placebo group. KARDIA-1 did not answer previous concerns about zilebesiran; (i) what happens during volume depletion, sepsis, and pregnancy when angiotensinogen is inhibited long-term or (ii) will it be effective in a high sodium diet.

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
New P1 trial:  A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers (clinicaltrials.gov) -  Nov 5, 2024
P1, N=78, Not yet recruiting,  Sponsor: Alnylam Pharmaceuticals

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Trial completion:  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (clinicaltrials.gov) -  Oct 16, 2024
P2, N=672, Completed,  Sponsor: Alnylam Pharmaceuticals
KARDIA-1 did not answer previous concerns about zilebesiran; (i) what happens during volume depletion, sepsis, and pregnancy when angiotensinogen is inhibited long-term or (ii) will it be effective in a high sodium diet. Active, not recruiting --> Completed

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Home Blood Pressure Reductions With Zilebesiran In Patients With Mild-To-Moderate Hypertension Are Consistent With Ambulatory And Office Blood Pressure Reductions In The KARDIA-1 Study (Zone 1' Moderated Digital Poster 1) - Oct 7, 2024 - Abstract #AHA2024AHA_5307;

|||||||||| Journal: Options for patients with out-of-control blood pressure: after all avenues have been exhausted. (Pubmed Central) - Sep 11, 2024
Comorbid conditions should be treated as appropriate with sodium-glucose-cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, sacubitril-valsartan or finerenone...The endothelin antagonist aprocitentan may be a final option in some countries. Of the drugs in development, the RNA based therapeutics that inhibit angiotensinogen synthesis appear to be some of the most promising.

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Enrollment closed:  ALN-AGT01-006: A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension (clinicaltrials.gov) -  Aug 28, 2024
P1/2, N=36, Active, not recruiting,  Sponsor: Alnylam Pharmaceuticals
Of the drugs in development, the RNA based therapeutics that inhibit angiotensinogen synthesis appear to be some of the most promising. Recruiting --> Active, not recruiting

|||||||||| Review, Journal: RNA interference therapy in cardiology: will new targets improve therapeutic goals? (Pubmed Central) - Aug 27, 2024
Zilebesiran, which targets hepatic angiotensinogen mRNA, has demonstrated a dose-related reduction in serum angiotensinogen levels, thereby lowering blood pressure in patients with systemic arterial hypertension...In the future, larger studies will provide insights into improvements in cardiovascular outcomes, long-term safety and broader applications in the general population. This review highlights the historical timeline of the development of siRNA-based drugs, their clinical indications, potential side-effects and future perspectives.

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Trial completion date:  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (clinicaltrials.gov) -  Jun 28, 2024
P2, N=672, Active, not recruiting,  Sponsor: Alnylam Pharmaceuticals
This review highlights the historical timeline of the development of siRNA-based drugs, their clinical indications, potential side-effects and future perspectives. Trial completion date: Dec 2025 --> Sep 2024

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Enrollment open:  ALN-AGT01-006: A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension (clinicaltrials.gov) -  Jun 28, 2024
P1/2, N=36, Recruiting,  Sponsor: Alnylam Pharmaceuticals
Trial completion date: Dec 2025 --> Sep 2024 Not yet recruiting --> Recruiting

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Journal: Clinical experience of Tianxiong Granules in treatment of hypertension based on treatment principle of supressing Yang and promoting blood circulation (Pubmed Central) - May 30, 2024
Despite continuous progress in modern medicine in the treatment of hypertension with new antihypertensive drugs such as Zilebesiran, a nucleic acid drug that acts on microRNA, direct renin inhibitors, and renal sympathetic blockade, the control rate is still not ideal...Some drugs can be used in sufficient quantities. By analyzing the compatibility of Tianxiong Granules, clinical application indications, combined formula experience, and dosage application experience, we provide effective treatment methods and more options for TCM to treat hypertension with Yang hyperactivity and blood stasis syndrome.

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
New P1/2 trial:  ALN-AGT01-006: A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension (clinicaltrials.gov) -  May 21, 2024
P1/2, N=36, Not yet recruiting,  Sponsor: Alnylam Pharmaceuticals

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche, IONIS-AGT-LRx / Ionis
Injectable angiotensinogen inhibition therapy for hypertension: a systematic review and meta-analysis (Station 7 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_4571;
Conclusions In this meta-analysis of RCTs, injectable AGT inhibitors were associated with a significant decrease in mean AGT, SBP, and DBP as compared with placebo. There were no significant differences between groups in serious adverse events, although injection site reaction was more common in patients treated with injectable AGT inhibitors.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive (Science Box 4 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_1183;
SBP reduction was consistent across most subgroups. Treatment with zilebesiran combined with standard antihypertensives may be effective for a broad population of patients with hypertension uncontrolled on monotherapy.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension - Primary Results From The Phase 2 Kardia-2 Study (Hall B-1 Main Tent) - Mar 25, 2024 - Abstract #ACC2024ACC_8867;
Treatment with zilebesiran combined with standard antihypertensives may be effective for a broad population of patients with hypertension uncontrolled on monotherapy. There is no abstract associated with this presentation.

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
Enrollment open:  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (clinicaltrials.gov) -  Mar 12, 2024
P2, N=390, Recruiting,  Sponsor: Alnylam Pharmaceuticals
There is no abstract associated with this presentation. Not yet recruiting --> Recruiting

|||||||||| Review, Journal: Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. (Pubmed Central) - Mar 5, 2024
Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Review, Journal: KEY HYPERTENSION BREAKTHROUGHS AND EMERGING TRENDS FROM THE AHA SCIENTIFIC SESSIONS. (Pubmed Central) - Mar 4, 2024
Furthermore, the KARDIA-1 study introduces us to Zilebesiran, an innovative RNA interference drug...The IMPACTS trial and the "Hypertension Treatment in Nigeria Program" demonstrate the effectiveness of implementing comprehensive blood pressure control strategies in real-world settings. These studies highlight the feasibility and scalability of such interventions, especially in low-resource environments, and their potential to significantly improve public health outcomes.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Journal: Zilebesiran: A Promising Antihypertensive Therapy Inhibiting Angiotensinogen Synthesis. (Pubmed Central) - Feb 22, 2024
Researchers also demonstrated a promising safety profile, as most of the adverse events were mild to moderate in nature. Phase II trials assessing efficacy and optimal dosing are currently underway, with a predicted completion by 2025.

||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche
New P2 trial:  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (clinicaltrials.gov) -  Feb 22, 2024
P2, N=390, Not yet recruiting,  Sponsor: Alnylam Pharmaceuticals

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Clinical, Journal: RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. (Pubmed Central) - Feb 16, 2024
P2
In adults with mild to moderate hypertension, treatment with zilebesiran across a range of doses at 3-month or 6-month intervals significantly reduced 24-hour mean ambulatory SBP at month 3. ClinicalTrials.gov Identifier: NCT04936035.

|||||||||| zilebesiran (ALN-AGT) / Alnylam, Roche
Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension - Primary Results From The Phase 2 KARDIA-2 Study (Hall B-1 Main Tent) - Feb 5, 2024 - Abstract #ACC2024ACC_8187;
ClinicalTrials.gov Identifier: NCT04936035. Abstract is embargoed at this time.



	Diseases Companies Products Productz Mechanisms of Action Sites